All in all, Ingrezza pulled in $2.3 billion in 2024, making for an “all-time record growth year” for the drug, Benevich noted. Teva's Austedo, meanwhile, collected $1.6 billion in sales last year.

INGREZZA Sales Guidance for 2025: $2.5 billion to $2.6 billion, reflecting $250 million growth at the midpoint. CRENESSITY Q4 2024 Sales: $2 million in net sales from initial bottle orders.

He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

FY25 revenue consensus $2.79B. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock ...

From a commercial perspective, INGREZZA continues to set the standard. Eight years after introducing the first treatment for tardive dyskinesia, we're on track to once again achieve double-digit ...

Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan ...

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...